Literature DB >> 33489698

Whole brain radiation therapy for primary central nervous system marginal zone lymphoma: a case report.

Genki Edward Sato1, Itaru Ikeda1, Marie Sakoda1, Kiyotomo Matsugi1, Takahiko Utsumi2, Yoko Iwasa3, Chikako Yamauchi1.   

Abstract

A standard radiation therapy protocol for primary central nervous system marginal zone lymphoma (CNS-MZL) has not been established. The International Lymphoma Radiation Oncology Group suggested a radiation therapy dose of 30-36 Gy for lesions of well-defined CNS-MZL. We report a case of relatively low-dose whole brain radiation therapy (WBRT) for ill-defined CNS-MZL. A 56-year-old man who presented with sudden left-sided convulsions and impaired consciousness was diagnosed with CNS-MZL. The tumor had an ill-defined lesion, without cerebrospinal fluid involvement. WBRT, consisting of 25.2 Gy in 14 fractions, was administered owing to the difficulty in target delineation for focal radiation therapy. No chemotherapy was administered during the treatment course. After the 36-month follow-up period, the patient maintained complete remission without neurological disorders. This report describes the usefulness of relatively low-dose WBRT for ill-defined CNS-MZL. © The Japan Society of Clinical Oncology 2020.

Entities:  

Keywords:  CNS lymphoma; Dural lymphoma; MALT lymphoma; Marginal zone lymphoma; Whole brain radiation therapy

Year:  2020        PMID: 33489698      PMCID: PMC7797388          DOI: 10.1007/s13691-020-00443-1

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  8 in total

1.  Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group.

Authors:  Joachim Yahalom; Tim Illidge; Lena Specht; Richard T Hoppe; Ye-Xiong Li; Richard Tsang; Andrew Wirth
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-05-01       Impact factor: 7.038

2.  Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences.

Authors:  Macarena I de la Fuente; Aya Haggiagi; Adrienne Moul; Robert J Young; Charif Sidani; Arnold Markoe; Francisco Vega; Lisa M DeAngelis; Izidore S Lossos
Journal:  Leuk Lymphoma       Date:  2016-09-21

3.  Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma.

Authors:  Pang-Hsien Tu; Caterina Giannini; Alexander R Judkins; Jason M Schwalb; Richard Burack; Brian P O'Neill; Anthony T Yachnis; Peter C Burger; Bernd W Scheithauer; Arie Perry
Journal:  J Clin Oncol       Date:  2005-07-11       Impact factor: 44.544

4.  Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients.

Authors:  Fabio M Iwamoto; Lisa M DeAngelis; Lauren E Abrey
Journal:  Neurology       Date:  2006-06-13       Impact factor: 9.910

Review 5.  Primary dural lymphomas: a review.

Authors:  Fabio M Iwamoto; Lauren E Abrey
Journal:  Neurosurg Focus       Date:  2006-11-15       Impact factor: 4.047

Review 6.  Low-dose and limited-volume radiotherapy alone for primary dural marginal zone lymphoma: treatment approach and review of published data.

Authors:  Dev R Puri; Welela Tereffe; Joachim Yahalom
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-01-30       Impact factor: 7.038

Review 7.  Extranodal Marginal Zone Lymphoma of the Central Nervous System.

Authors:  Adanma Ayanambakkam; Sami Ibrahimi; Khalid Bilal; Mohamad A Cherry
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-09-23

8.  An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement.

Authors:  Andrew J Sunderland; Raphael E Steiner; Musa Al Zahrani; Chelsea C Pinnix; Bouthaina Shbib Dabaja; Jillian R Gunther; Loretta J Nastoupil; Mats Jerkeman; David Joske; Gavin Cull; Tarec El-Galaly; Diego Villa; Chan Yoon Cheah
Journal:  Cancer Med       Date:  2019-12-05       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.